Published in Am J Physiol Heart Circ Physiol on September 01, 2002
cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev (2010) 3.27
Evidence for mitochondrial K+ channels and their role in cardioprotection. Circ Res (2004) 2.06
Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta. J Biol Chem (2008) 1.93
Mitochondrial ion channels. Annu Rev Physiol (2007) 1.70
Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling. Br J Pharmacol (2007) 1.52
ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice. Am J Physiol Heart Circ Physiol (2009) 1.45
Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. Proc Natl Acad Sci U S A (2010) 1.41
Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia/reperfusion through protein-kinase g-dependent generation of hydrogen sulfide. Circulation (2009) 1.40
Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency. Proc Natl Acad Sci U S A (2008) 1.29
Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits. J Mol Cell Cardiol (2006) 1.27
Cardioprotection afforded by chronic exercise is mediated by the sarcolemmal, and not the mitochondrial, isoform of the KATP channel in the rat. J Physiol (2005) 1.24
Sildenafil-mediated neovascularization and protection against myocardial ischaemia reperfusion injury in rats: role of VEGF/angiopoietin-1. J Cell Mol Med (2008) 1.21
Fiber type-specific nitric oxide protects oxidative myofibers against cachectic stimuli. PLoS One (2008) 1.10
Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect. J Pharmacol Exp Ther (2010) 1.09
PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. Pharmacol Ther (2014) 1.02
Protective effects of sildenafil administration on testicular torsion/detorsion damage in rats. World J Urol (2008) 1.01
Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T. BMC Pharmacol (2005) 1.01
Alterations in mitochondrial function as a harbinger of cardiomyopathy: lessons from the dystrophic heart. J Mol Cell Cardiol (2009) 0.99
Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts. Acta Pharmacol Sin (2008) 0.99
Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases. Exp Clin Cardiol (2011) 0.97
Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway. Am J Physiol Heart Circ Physiol (2011) 0.97
Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection. J Am Coll Cardiol (2012) 0.95
Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide. Am J Physiol Heart Circ Physiol (2012) 0.95
Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells. Mol Pharmacol (2013) 0.95
Role of microRNAs in cardiac preconditioning. J Cardiovasc Pharmacol (2010) 0.94
Protective effect of sildenafil citrate on contralateral testis injury after unilateral testicular torsion/detorsion. Clinics (Sao Paulo) (2011) 0.94
Roles of the nitric oxide signaling pathway in cardiac ischemic preconditioning against myocardial ischemia-reperfusion injury. Med Sci Monit (2011) 0.93
PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells. Cancer Biol Ther (2014) 0.92
Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat. Br J Pharmacol (2007) 0.92
Vardenafil protects isolated rat hearts at reperfusion dependent on GC and PKG. Br J Pharmacol (2008) 0.89
Clinical and molecular genetics of the phosphodiesterases (PDEs). Endocr Rev (2013) 0.89
Phospholemman Ser69 phosphorylation contributes to sildenafil-induced cardioprotection against reperfusion injury. Am J Physiol Heart Circ Physiol (2010) 0.88
Sildenafil (Viagra) reduces arrhythmia severity during ischaemia 24 h after oral administration in dogs. Br J Pharmacol (2004) 0.88
Phosphodiesterase-5 inhibition mimics intermittent reoxygenation and improves cardioprotection in the hypoxic myocardium. PLoS One (2011) 0.88
Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials. Curr Heart Fail Rep (2012) 0.87
Targeted disruption of PDE3B, but not PDE3A, protects murine heart from ischemia/reperfusion injury. Proc Natl Acad Sci U S A (2015) 0.86
Anti-inflammatory and cardioprotective effects of tadalafil in diabetic mice. PLoS One (2012) 0.86
Sirtuin 1 (SIRT1) activation mediates sildenafil induced delayed cardioprotection against ischemia-reperfusion injury in mice. PLoS One (2014) 0.86
Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase. Br J Pharmacol (2007) 0.85
Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications. J Cardiovasc Transl Res (2010) 0.85
Long-acting phosphodiesterase-5 inhibitor, tadalafil, induces sustained cardioprotection against lethal ischemic injury. Am J Physiol Heart Circ Physiol (2009) 0.82
The protective effects of a phosphodiesterase 5 inhibitor, sildenafil, on postresuscitation cardiac dysfunction of cardiac arrest: metabolic evidence from microdialysis. Crit Care (2014) 0.81
The effects of tadalafil on renal ischemia reperfusion injury: an experimental study. Bosn J Basic Med Sci (2011) 0.81
Therapeutic potential of PDE modulation in treating heart disease. Future Med Chem (2013) 0.80
Adenosine A(1) receptor mediates delayed cardioprotective effect of sildenafil in mouse. J Mol Cell Cardiol (2007) 0.80
Attenuation of Doxorubicin-induced Cardiotoxicity by Tadalafil: A Long Acting Phosphodiesterase-5 Inhibitor. Mol Cell Pharmacol (2010) 0.79
Sildenafil attenuates hepatocellular injury after liver ischemia reperfusion in rats: a preliminary study. Oxid Med Cell Longev (2014) 0.79
Sildenafil stimulates the expression of gaseous monoxide-generating enzymes in vascular smooth muscle cells via distinct signaling pathways. Biochem Pharmacol (2012) 0.79
Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality. Heart (2016) 0.77
Cardioprotective actions of cyclic GMP: lessons from genetic animal models. Hypertension (2009) 0.77
Old dog, new tricks: novel cardiac targets and stress regulation by protein kinase G. Cardiovasc Res (2016) 0.76
Beetroot juice reduces infarct size and improves cardiac function following ischemia-reperfusion injury: Possible involvement of endogenous H2S. Exp Biol Med (Maywood) (2014) 0.76
Impact of Mitochondrial Ca2+-Sensitive Potassium (mBKCa) Channels in Sildenafil-Induced Cardioprotection in Rats. PLoS One (2015) 0.76
Understanding of chest pain in microvascular disease proved by cardiac magnetic resonance image (UMPIRE): study protocol for a randomized controlled trial. Trials (2014) 0.76
Sildenafil reduces alcohol-induced gastric damage: just say 'NO'. Br J Pharmacol (2007) 0.75
The protective effect of tadalafil on IMA (ischemia modified albumin) levels in experimental renal ischemia-reperfusion injury. Int J Clin Exp Med (2015) 0.75
Effect of sildenafil citrate in nicotine-induced ischemia: An experimental study using a rat model. Can J Plast Surg (2013) 0.75
Sildenafil augments early protective transcriptional changes after ischemia in mouse myocardium. Gene (2008) 0.75
Neuroprotective effects of tadalafil on gerbil dopaminergic neurons following cerebral ischemia. Neural Regen Res (2013) 0.75
Priming the proteasome by protein kinase G: a novel cardioprotective mechanism of sildenafil. Future Cardiol (2015) 0.75
How does Viagra protect the ischemic heart? Am J Physiol Heart Circ Physiol (2009) 0.75
PDE5 Inhibitor Tadalafil and Hydroxychloroquine Cotreatment Provides Synergistic Protection against Type 2 Diabetes and Myocardial Infarction in Mice. J Pharmacol Exp Ther (2017) 0.75
Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction. Heart (2017) 0.75
HIF-1 activation attenuates postischemic myocardial injury: role for heme oxygenase-1 in modulating microvascular chemokine generation. Am J Physiol Heart Circ Physiol (2005) 2.43
Rapamycin confers preconditioning-like protection against ischemia-reperfusion injury in isolated mouse heart and cardiomyocytes. J Mol Cell Cardiol (2006) 2.28
Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation (2008) 2.23
Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation (2005) 2.18
Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem (2005) 2.12
Hypoxia inducible factor-1 activation by prolyl 4-hydroxylase-2 gene silencing attenuates myocardial ischemia reperfusion injury. Circ Res (2005) 1.99
Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res (2003) 1.99
Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta. J Biol Chem (2008) 1.93
Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am J Physiol Heart Circ Physiol (2008) 1.86
Endogenous microRNAs induced by heat-shock reduce myocardial infarction following ischemia-reperfusion in mice. FEBS Lett (2008) 1.77
A novel role of microRNA in late preconditioning: upregulation of endothelial nitric oxide synthase and heat shock protein 70. Circ Res (2009) 1.69
Dietary nitrate supplementation protects against Doxorubicin-induced cardiomyopathy by improving mitochondrial function. J Am Coll Cardiol (2011) 1.66
Jugular venous valved conduit (Contegra) matches allograft performance in infant truncus arteriosus repair. Eur J Cardiothorac Surg (2008) 1.45
ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice. Am J Physiol Heart Circ Physiol (2009) 1.45
Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. Proc Natl Acad Sci U S A (2010) 1.41
Mitochondrial-targeted Signal transducer and activator of transcription 3 (STAT3) protects against ischemia-induced changes in the electron transport chain and the generation of reactive oxygen species. J Biol Chem (2011) 1.40
Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia/reperfusion through protein-kinase g-dependent generation of hydrogen sulfide. Circulation (2009) 1.40
Cyclic GMP-dependent protein kinase Ialpha attenuates necrosis and apoptosis following ischemia/reoxygenation in adult cardiomyocyte. J Biol Chem (2006) 1.33
Prediction of subcellular localization using sequence-biased recurrent networks. Bioinformatics (2005) 1.32
Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications. Vascul Pharmacol (2005) 1.27
Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits. J Mol Cell Cardiol (2006) 1.27
NFIA controls telencephalic progenitor cell differentiation through repression of the Notch effector Hes1. J Neurosci (2010) 1.24
Cobalt chloride induces delayed cardiac preconditioning in mice through selective activation of HIF-1alpha and AP-1 and iNOS signaling. Am J Physiol Heart Circ Physiol (2004) 1.23
Protein kinase C plays an essential role in sildenafil-induced cardioprotection in rabbits. Am J Physiol Heart Circ Physiol (2004) 1.22
cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther (2009) 1.22
Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy. J Mol Cell Cardiol (2004) 1.18
Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial K(ATP) channels in rabbits. J Mol Cell Cardiol (2006) 1.18
Left ventricular systolic dysfunction induced by ventricular ectopy: a novel model for premature ventricular contraction-induced cardiomyopathy. Circ Arrhythm Electrophysiol (2011) 1.17
Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect. J Pharmacol Exp Ther (2010) 1.09
Loss of myocardial ischemic postconditioning in adenosine A1 and bradykinin B2 receptors gene knockout mice. Circulation (2008) 1.08
Activation of hypoxia-inducible factor-1 via prolyl-4 hydoxylase-2 gene silencing attenuates acute inflammatory responses in postischemic myocardium. Am J Physiol Heart Circ Physiol (2007) 1.05
Preconditioning by phosphodiesterase-5 inhibition improves therapeutic efficacy of adipose-derived stem cells following myocardial infarction in mice. Stem Cells (2012) 1.05
Protein kinase C-delta mediates adenosine A3 receptor-induced delayed cardioprotection in mouse. Am J Physiol Heart Circ Physiol (2003) 1.03
Essential role of mitochondrial Ca2+-activated and ATP-sensitive K+ channels in sildenafil-induced late cardioprotection. J Mol Cell Cardiol (2007) 1.02
Late preconditioning elicited by activation of adenosine A(3) receptor in heart: role of NF- kappa B, iNOS and mitochondrial K(ATP) channel. J Mol Cell Cardiol (2002) 1.01
Opening of Ca2+-activated K+ channels triggers early and delayed preconditioning against I/R injury independent of NOS in mice. Am J Physiol Heart Circ Physiol (2004) 1.00
Ischemic preconditioning and morphine attenuate myocardial apoptosis and infarction after ischemia-reperfusion in rabbits: role of delta-opioid receptor. Am J Physiol Heart Circ Physiol (2004) 0.99
Hypoxia inducible factor-1 upregulates adiponectin in diabetic mouse hearts and attenuates post-ischemic injury. J Cardiovasc Pharmacol (2008) 0.97
Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway. Am J Physiol Heart Circ Physiol (2011) 0.97
Mammalian target of rapamycin (mTOR) inhibition with rapamycin improves cardiac function in type 2 diabetic mice: potential role of attenuated oxidative stress and altered contractile protein expression. J Biol Chem (2013) 0.96
Sildenafil citrate (viagra) induces cardioprotective effects after ischemia/reperfusion injury in infant rabbits. Pediatr Res (2004) 0.96
Right ventricular cardiomyocyte apoptosis in patients with acute myocardial infarction of the left ventricular wall. Am J Cardiol (2008) 0.95
Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells. Mol Pharmacol (2013) 0.95
Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide. Am J Physiol Heart Circ Physiol (2012) 0.95
Role of microRNAs in cardiac preconditioning. J Cardiovasc Pharmacol (2010) 0.94
eNOS phosphorylation: a pivotal molecular switch in vasodilation and cardioprotection? J Mol Cell Cardiol (2006) 0.94
Rapamycin protects against myocardial ischemia-reperfusion injury through JAK2-STAT3 signaling pathway. J Mol Cell Cardiol (2012) 0.93
Silencing heat shock factor 1 by small interfering RNA abrogates heat shock-induced cardioprotection against ischemia-reperfusion injury in mice. J Mol Cell Cardiol (2005) 0.91
The inflammasome in myocardial injury and cardiac remodeling. Antioxid Redox Signal (2014) 0.90
Type 2 diabetic obese db/db mice are refractory to myocardial ischaemic post-conditioning in vivo: potential role for Hsp20, F1-ATPase δ and Echs1. J Cell Mol Med (2012) 0.89
Identification of protein targets underlying dietary nitrate-induced protection against doxorubicin cardiotoxicity. J Cell Mol Med (2011) 0.88
Krüppel-like factor 2 is required for normal mouse cardiac development. PLoS One (2013) 0.88
Curcumin prevents cardiac remodeling secondary to chronic renal failure through deactivation of hypertrophic signaling in rats. Am J Physiol Heart Circ Physiol (2010) 0.87
Phosphodiesterase-5 inhibitor tadalafil attenuates oxidative stress and protects against myocardial ischemia/reperfusion injury in type 2 diabetic mice. Free Radic Biol Med (2013) 0.87
Anti-inflammatory and cardioprotective effects of tadalafil in diabetic mice. PLoS One (2012) 0.86
Improvement of cardiac function with parecoxib, a cyclo-oxygenase-2 inhibitor, in a rat model of ischemic heart failure. J Cardiovasc Pharmacol (2007) 0.86
Dietary inorganic nitrate alleviates doxorubicin cardiotoxicity: mechanisms and implications. Nitric Oxide (2012) 0.85
Remote ischemic preconditioning for myocardial protection: update on mechanisms and clinical relevance. Mol Cell Biochem (2015) 0.85
Chronic treatment with long acting phosphodiesterase-5 inhibitor tadalafil alters proteomic changes associated with cytoskeletal rearrangement and redox regulation in Type 2 diabetic hearts. Basic Res Cardiol (2012) 0.85
Hypercholesterolemia enhances tolerance to lethal systemic hypoxia in middle-aged mice: possible role of VEGF downregulation in brain. Mol Cell Biochem (2006) 0.84
Alpha-adrenergic receptor stimulation produces late preconditioning through inducible nitric oxide synthase in mouse heart. J Mol Cell Cardiol (2002) 0.82
Inhibition of mammalian target of rapamycin protects against reperfusion injury in diabetic heart through STAT3 signaling. Basic Res Cardiol (2015) 0.82
Phosphodiesterase inhibition in heart failure. Handb Exp Pharmacol (2011) 0.81
Evidence that NOS2 acts as a trigger and mediator of late preconditioning induced by acute systemic hypoxia. Am J Physiol Heart Circ Physiol (2002) 0.81
Sildenafil-induced cardioprotection in rabbits. Cardiovasc Res (2003) 0.80
Adenosine A(1) receptor mediates delayed cardioprotective effect of sildenafil in mouse. J Mol Cell Cardiol (2007) 0.80
Studies on the inference of protein binding regions across fold space based on structural similarities. Proteins (2011) 0.80
Cardiac regenerative potential of adipose tissue-derived stem cells. Acta Physiol Hung (2009) 0.80
Tadalafil prevents acute heart failure with reduced ejection fraction in mice. Cardiovasc Drugs Ther (2014) 0.79
Synergistic effects of atorvastatin and sildenafil in cardioprotection--role of NO. Cardiovasc Drugs Ther (2006) 0.79
Attenuation of Doxorubicin-induced Cardiotoxicity by Tadalafil: A Long Acting Phosphodiesterase-5 Inhibitor. Mol Cell Pharmacol (2010) 0.79
Protective effects of parecoxib, a cyclo-oxygenase-2 inhibitor, in postinfarction remodeling in the rat. J Cardiovasc Pharmacol (2007) 0.79
A simple and sensitive HPLC fluorescence method for determination of tadalafil in mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 0.78
Hydrogen sulfide mediates the cardioprotective effects of gene therapy with PKG-Iα. Basic Res Cardiol (2015) 0.77
Mechanism of reactive oxygen species generation after opening of mitochondrial KATP channels. Am J Physiol Heart Circ Physiol (2006) 0.77
cis-3, 4', 5-Trimethoxy-3'-aminostilbene disrupts tumor vascular perfusion without damaging normal organ perfusion. Cancer Chemother Pharmacol (2008) 0.77
Genetic deletion of fas receptors or Fas ligands does not reduce infarct size after acute global ischemia-reperfusion in isolated mouse heart. Cell Biochem Biophys (2006) 0.76
Phosphodiesterase-5 and retargeting of subcellular cGMP signaling during pathological hypertrophy. Circulation (2012) 0.76
Pretreatment with tyrosine kinase inhibitor attenuates the reduction of apoptosis 24 h after ischemic preconditioning. Jpn J Physiol (2004) 0.76
NFkappaB activation during ischemia/reperfusion in heart: friend or foe? J Mol Cell Cardiol (2002) 0.75
Commentaries on viewpoint: effect of altitude on leptin, does it go up or down? J Appl Physiol (1985) (2008) 0.75
Ataxia-telangiectasia mutated kinase: a potential new target for suppressing inflammation in heart failure? J Am Heart Assoc (2014) 0.75
A better freedom-of-choice plan, and how your patients and practice can benefit from it. Tex Dent J (2010) 0.75
Improved access to sequential motifs: a note on the architectural bias of recurrent networks. IEEE Trans Neural Netw (2005) 0.75